FDA Regulatory Affairs Head Glavin Makes Retooling Of Field Force A Priority
Management of FDA's field resources will be a top priority for Associate Commissioner for Regulatory Affairs Margaret Glavin as she undertakes a wide-ranging review of office practices
You may also be interested in...
FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011